Overcoming matrix interference: ADA immunoassays using an automated nanoliter platform

In this webinar, Sally Ye, Boehringer Ingelheim Pharmaceuticals, Inc., present strategies for choosing the right bioanalytical platform to optimize clinical ADA assay method development.

Matrix interference in anti-drug antibody (ADA) assays can present challenges in assay development and data analysis, particularly in clinical study samples. One strategy for reducing matrix interference is the utilization of a nanoliter-scale, flow-through microfluidic immunoassay platform.

This webinar presents a case study highlighting the advantages of using the Gyrolab® platform in clinical ADA method development to minimize matrix interference. The case study will also compare this platform to other assay formats and platforms that are commonly used in clinical ADA method development.

Speakers:

Ellen Lee, Gyros Protein Technologies
Sally Ye, Boehringer Ingelheim Pharmaceuticals, Inc.

If you have problems viewing the webinar, please contact maritha.lundin@gyrosproteintech.com